NCT06303713 is a Phase 1 clinical trial of Carboplatin in Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT06303713?

NCT06303713 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT06303713?

Interventions in NCT06303713: Carboplatin, 177Lu-PSMA-617.

What condition does NCT06303713 study?

NCT06303713 studies Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer.

Is NCT06303713 still recruiting?

NCT06303713 is currently active, enrolled. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT06303713

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Active, enrolled Phase 1 Last updated 8 April 2026

What this trial tests

Phase 1 trial testing Carboplatin in Prostate Cancer in 37 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 May 2024

Primary endpoint
19 October 2026

19 March 2027

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	22 May 2024
Primary completion	19 October 2026
Estimated completion	19 March 2027
Sites	3 locations across United States

Drugs / interventions tested

Carboplatin (Carboplatin) — full drug profile →
177Lu-PSMA-617 — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →
Metastatic Castration-resistant Prostate Cancer — all drugs for Metastatic Castration-resistant Prostate Cancer →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, male only, with Prostate Cancer or Metastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether the combination is effective in shrinking or preventing growth of prostate cancer. The names of the study drugs used in this research study are: * Carboplatin (A type of chemotherapy) * 177Lu-PSMA-617 (A type of radioligand therapy)

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.
Francini E, Agarwal N, Castro E, Cheng HH, et al · · 2025 · cited 21× · PMID 39306478 · DOI 10.1016/j.eururo.2024.09.008
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.
Khorasanchi A, Hong F, Yang Y, Singer EA, et al · · 2025 · cited 12× · PMID 40051495 · DOI 10.20517/cdr.2024.173
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies.
Li J, Hu J, Yang Y, Zhang H, et al · · 2025 · cited 5× · PMID 41247642 · DOI 10.1186/s43556-025-00352-w
Current and future perspectives on radioligand therapy in advanced prostate cancer.
Ahmed B, Ravi P. · · 2026 · PMID 41536963 · DOI 10.1177/17588359251409047

Verify or expand the search:

Other trials of Carboplatin

Trials testing the same drug.

NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06303713 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06303713.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing